Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. Click here to find out why LFVN stock is a ...

But one Cleveland Clinic expert is imploring executives not to look away. "Preventive measures are often neglected because they don't generate revenue, but they are incredibly important," Leslie Cho, ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...